WO2012006634A3 - Prostate specific antigen (psa) peptide therapy - Google Patents

Prostate specific antigen (psa) peptide therapy Download PDF

Info

Publication number
WO2012006634A3
WO2012006634A3 PCT/US2011/043598 US2011043598W WO2012006634A3 WO 2012006634 A3 WO2012006634 A3 WO 2012006634A3 US 2011043598 W US2011043598 W US 2011043598W WO 2012006634 A3 WO2012006634 A3 WO 2012006634A3
Authority
WO
WIPO (PCT)
Prior art keywords
psa
specific antigen
prostate specific
peptide therapy
peptide
Prior art date
Application number
PCT/US2011/043598
Other languages
French (fr)
Other versions
WO2012006634A2 (en
Inventor
Supriya M. Perambakam
David J. Peace
Original Assignee
The Board Of Trustees Of The University Of Illiniois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The University Of Illiniois filed Critical The Board Of Trustees Of The University Of Illiniois
Publication of WO2012006634A2 publication Critical patent/WO2012006634A2/en
Priority to US13/413,242 priority Critical patent/US8557777B2/en
Publication of WO2012006634A3 publication Critical patent/WO2012006634A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464494—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)

Abstract

The present invention is directed to compositions and methods for treating prostate cancer.
PCT/US2011/043598 2010-07-09 2011-07-11 Prostate specific antigen (psa) peptide therapy WO2012006634A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/413,242 US8557777B2 (en) 2010-07-09 2012-03-06 Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36309110P 2010-07-09 2010-07-09
US61/363,091 2010-07-09
US201061426321P 2010-12-22 2010-12-22
US61/426,321 2010-12-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/413,242 Continuation-In-Part US8557777B2 (en) 2010-07-09 2012-03-06 Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides

Publications (2)

Publication Number Publication Date
WO2012006634A2 WO2012006634A2 (en) 2012-01-12
WO2012006634A3 true WO2012006634A3 (en) 2012-05-31

Family

ID=45441875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/043598 WO2012006634A2 (en) 2010-07-09 2011-07-11 Prostate specific antigen (psa) peptide therapy

Country Status (1)

Country Link
WO (1) WO2012006634A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
WO2013142390A1 (en) * 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
BR112014032728A2 (en) 2012-06-27 2017-11-28 Berg Llc use of markers in the diagnosis and treatment of prostate cancer
CN105163754B (en) * 2012-09-20 2018-01-05 王荣福 Prostate specific tumour antigen and application thereof
EP2958588B1 (en) 2013-02-22 2017-08-23 CureVac AG Combination of vaccination and inhibition of the pd-1 pathway
SG11201506052PA (en) * 2013-02-22 2015-09-29 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
US10894963B2 (en) 2013-07-25 2021-01-19 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
WO2015135558A1 (en) 2014-03-12 2015-09-17 Curevac Gmbh Combination of vaccination and ox40 agonists
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
SG11201704660YA (en) 2014-12-08 2017-07-28 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
PT3240801T (en) * 2014-12-31 2021-02-18 Checkmate Pharmaceuticals Inc Combination tumor immunotherapy
RU2017145558A (en) * 2015-05-29 2019-07-01 Мерк Шарп И Доум Корп. COMBINATION OF ANTAGONIST PD-1 AND OLIGONUCLEOTIDE TYPE CPG-C FOR CANCER TREATMENT
AU2017261354A1 (en) * 2016-05-06 2018-11-29 Exicure Operating Company Spherical Nucleic Acid TLR9 agonists

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807978A (en) * 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
CA2389176A1 (en) * 1999-10-28 2001-05-17 Immunolytics Inc. A method and composition for treating prostate cancer
CA2468258A1 (en) * 2001-11-30 2003-06-12 Jeffrey Schlom Peptide agonists of prostate-specific antigen, and uses therefor
US6689355B2 (en) * 2000-05-11 2004-02-10 Altarex Corp. Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
CA2319252C (en) * 1998-01-21 2004-11-30 Brigham And Women's Hospital, Inc. Circulating insulin-like growth factor-i and prostate cancer risk
US7288636B2 (en) * 1997-04-30 2007-10-30 Hybritech Incorporated Forms of prostate specific antigens and methods for their detection
CA2731823A1 (en) * 2008-07-25 2010-01-28 The Johns Hopkins University Detection of prostate cancer using psa glycosylation patterns
CA2748823A1 (en) * 2009-01-06 2010-07-15 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for the identification, monitoring, and treatment of prostate cancer

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807978A (en) * 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US7288636B2 (en) * 1997-04-30 2007-10-30 Hybritech Incorporated Forms of prostate specific antigens and methods for their detection
CA2319252C (en) * 1998-01-21 2004-11-30 Brigham And Women's Hospital, Inc. Circulating insulin-like growth factor-i and prostate cancer risk
CA2389176A1 (en) * 1999-10-28 2001-05-17 Immunolytics Inc. A method and composition for treating prostate cancer
US6689355B2 (en) * 2000-05-11 2004-02-10 Altarex Corp. Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
CA2468258A1 (en) * 2001-11-30 2003-06-12 Jeffrey Schlom Peptide agonists of prostate-specific antigen, and uses therefor
CA2731823A1 (en) * 2008-07-25 2010-01-28 The Johns Hopkins University Detection of prostate cancer using psa glycosylation patterns
CA2748823A1 (en) * 2009-01-06 2010-07-15 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for the identification, monitoring, and treatment of prostate cancer

Also Published As

Publication number Publication date
WO2012006634A2 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
WO2012006634A3 (en) Prostate specific antigen (psa) peptide therapy
EP2714081A4 (en) Methods, compositions, and kits for the treatment of cancer
WO2012078688A3 (en) Humanized antibodies to liv-1 and use of same to treat cancer
WO2011083090A3 (en) Methods for treating breast cancer
IN2014KN00848A (en)
BR112013002012A2 (en) Methods and Compositions for Liver Cancer Therapy
NZ707086A (en) Anti-cd40 antibodies and methods of use
EP2734207A4 (en) Novel compositions and methods for treating prostate cancer
SG194701A1 (en) Anti-cd40 antibodies and methods of use
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
NZ584042A (en) Use of mva to treat prostate cancer
EA201201000A1 (en) METHODS OF TREATMENT OF COLORECTAL CANCER
AU2012335543A8 (en) HER3 antibodies and uses thereof
MX2011010955A (en) Adjuvant cancer therapy.
NZ611785A (en) Anti-notch1 antibodies
MY157341A (en) Methods and compositions for treating lung cancer
WO2011129936A3 (en) Compositions and methods for the prevention and treatment of cancer
MX2012013875A (en) Peripheral blood sparc antibodies and uses thereof.
WO2012079878A3 (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
MX2014001766A (en) Neuregulin antibodies and uses thereof.
ZA201300762B (en) Novel combination therapy for the treatment of cancer
WO2013072901A3 (en) Compositions and methods for treating glioma
WO2011097166A9 (en) Combination therapy for treating cancer comprising an igf-1r inhibitor and an hdac inhibitor
EP2635273A4 (en) Isoflavonoid compositions and methods for the treatment of cancer
WO2011153243A3 (en) Anti-angiogenesis therapy for treating gastric cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11804483

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11804483

Country of ref document: EP

Kind code of ref document: A2